

Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering Number of Hong Kong Offer Shares Number of International Offer Shares **Maximum Offer Price**

200,000,000 Shares (subject to reallocation and the Over-allotment Option) 20,000,000 Shares (subject to reallocation) 180,000,000 Shares (subject to reallocation and the Over-allotment Option) HK\$3.00 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars and subject to refund) HK\$0.01 per Share

Nominal value : HK\$0 Stock code : 1652

全球發售

200,000,000 股股份(可予重新分配及視乎超額配股權行使情况而定) 20,000,000 股股份(可予重新分配) 180,000,000 股股份(可予重新分配及視乎超額配股權行使情况而定) 每股發售股份3.00港元,另加1%經紀佣金、0.0027%證監會交易徵費及0.005%聯交所交易費 (須於申請時以港元繳足,多繳股款可予退還) 每股股份0.01港元 國際發售股份數目 最高發售價

面值 : 股份代號 : Application Form 申請表格

Please read carefully the prospectus of Fusen Pharmaceutical Company Limited (the "Company") dated Thursday, June 28, 2018 (the "Prospectus") (in particular, the section "How to Apply for Hong Kong Olfer Shares" in the Prospectus) and the guide on the back of this Application Form before completing this Application Form. Terms defined in the Prospectus together with any supplement thereto have the same meanings when used in this Application Form unless defined herein. Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and Hong Kong Securities Clearing Company Limited ("HKSCC") take no responsibility for the contents of this Application Form, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of this Application Form.

wnole or any part of this Application Form.

A copy of this Application Form, together with a copy of each of the WHITE and YELLOW Application Forms, the Prospectus and the other documents specified in the section headed "Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection" in Appendix V to the Prospectus, have been registered by the Registrar of Companies in Hong Kong as required by Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The Securities and Futures Commission (the "SFC") and the Registrar of Companies in Hong Kong take no responsibility as to the contents of any of these documents.

Your attention is drawn to the paragraph headed "Personal Data" in the section "How to Apply for Hong Kong Offer Shares" in the Prospectus which sets out the policies and practices of the Company and the Hong Kong Share Registrar in relation to personal data and compliance with the Personal Data (Privacy) Ordinance.

(Privacy) Ordinance.

Nothing in this Application Form or the Prospectus constitutes an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Hong Kong Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This Application Form and the Prospectus are not for distribution, directly or indirectly in or into the United States, nor is this application an offer of Shares for sale in the United States. The Offer Shares have not been and will not be registered under the U.S. Securities Act rany state securities law in the United States and may not be offered, sold, pledged or transferred within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities law. The Offer Shares may only be offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of each jurisdiction where those offers and sales occur. No public offering of the Offer Shares will be made in the United States.

This Application Form and the Prospectus may not be forwarded or distributed or reproduced (in part) in any manner whatsoever in any jurisdiction, This Application Form and the Prospectus in whole or in part) in any manner whatsoever in any jurisdiction. The Application Form and the Prospectus in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the U.S. Securities Act or the applicable laws of other jurisdictions.

To: Fusen Pharmaceutical Company Limited

Fusen Pharmaceutical Company Limited Sole Sponsor Joint Global Coordinators Joint Bookrunners Joint Lead Managers Hong Kong Underwriters

在填寫本申請表格前,請仔細閱讀福森藥業有限公司(「本公司」)於2018年6月28日(星期四)刊發的招股章程(打招股章程)(尤其是招股章程[如何申請香港發售股份)一節)及刊載於本申請表格背面的指引。除另有界定,本申請表格所使用詞彙與招股章程連同其任何補充文件所界定者具相同涵義。

香港交易及結算所有限公司、香港聯合交易所有限公司(「聯交所」)及香港中央結算有限公司(「香港結算」)對本申請表格內容概不負責,對其準確性或完整性亦不發表任何聲明,並明確表示概不會就因本申請表格全部或性何部分內容而產生或因依賴該等內容而引致的任何損失來辦任何責任

敬請 關下貿意招股章程「如何申請香港發售股份」一節內的「個人資料」一段,當中載有本公司及本公司的 香港證券登記處有關個人資料及遵守《個人資料(私隱)條例》的政策及慣例。

本申請表格或招股章程所載者概不構成出售要約或要約購買的游說,而在任何作出有關要約、游說或出售即關鍵法的司法權區內,概不得出售任何香港發售股份。本申請表格及招股章程不得在美國境內直接或門接源 第,而此項申請亦並非在美國地角股份的要約。發售股份並非亦將不會根據美國游戏或美國任何利證券法 發記,且不得在美國境內提呈發售、出售、抵押或轉讓,惟根據美國游券法及總用美國州遊券法獲縮免營設 規定或並非受該等營稅退定規股的交易條外。勞售股份以可依據美國游券法 另規例也計分號 及出售的各 司法權區適用法例在美國境外以鄰岸交易方式提呈發售及出售。將不會於美國進行發售股份的公開發售。

在任何根據有關司法權區法例不得發送、派發或複製本申請表格及招股章程之司法權區內,概不得以任何方式發送或派發或複製(全部或部分)本申請表格及招股章程。本申請表格及招股章程僅致予 關下本人。假不得發送或派發或複製本申請表格或招股章程的全部或部分。如未能遵守此項指令,可能違反美國證券法或其他司法權區的適用法例。

We confirm that we have (i) complied with the Guidelines for Electronic Public Offerings and the Operational Procedures for White Form eIPO Applications submitted via banks/stockbrokers and all applicable laws and regulations (whether statutory or otherwise) in relation to the provision of our White Form eIPO services in connection with the Hong Kong Public Offering; and (ii) read the terms and conditions and application procedures set out in the Prospectus and this Application Form and agree to be bound by them. Applying on behalf of each of the underlying applicants to whom this application relates, we:

- apply for the number of Hong Kong Offer Shares set out below, on the terms and conditions of the Prospectus and this Application Form, and subject to the Memorandum of Association and the Articles of Association;
- enclose payment in full for the Hong Kong Offer Shares applied for, including 1% brokerage, 0.0027% SFC transaction levy and 0.005% Stock Exchange trading fee;
- confirm that the underlying applicants have undertaken and agreed to accept the Hong Kong Offer Shares applied for, or any lesser number allocated to such underlying applicants on this application;
- undertake and confirm that the underlying applicant(s) and the person for whose benefit the underlying applicant(s) is/are applying; or has/have not applied for or taken up, or indicated an interest for, or received or been placed or allocated (including conditionally and/or provisionally), and will not apply for take up, or indicate an interest for, any Offer Shares under the International Offering nor participate in the International Offering;
- understand that these declarations and representations will be relied upon by the Company and the Joint Global Coordinators in deciding whether or not to make any allotment of Hong Kong Offer Shares in response to this application, and that the underlying applicants may be prosecuted if they made a false declaration:
- authorise the Company to place the name(s) of the underlying applicant(s) on the register of members of the Company as the holder(s) of any Hong Kong Offer Shares to be allotted to them, and our Company and/or its agent (subject to the terms and conditions set out in this Application Form) to send any share certificate(s) and/or any refund cheque and/or e-Refund payment instruction(s) (where applicable) to the that underlying applicant in accordance with the procedures prescribed in this Application Form and in the Prospectus except where the underlying applicant has applied for 1,000,000 or more Hong Kong Offer Shares and that underlying applicant has collected any Share certificate(s) in person in accordance with the procedures prescribed in this Application and in the Prospectus;
- Application and in the Prospectus;

 request that any e-Refund payment instructions be dispatched to the application payment account where the underlying applicants had paid the application monies from a single bank account;

 request that any refund cheque(s) be made payable to the underlying applicant(s) who had used multiple bank accounts to pay the application monies and to send any such refund cheque(s) by ordinary post at that underlying applicant's own risk to the address stated on the application in accordance with the procedures prescribed in this Application Form and in the Prospectus;
- **confirm** that each underlying applicant has read the terms and conditions and application procedures set out in this Application Form and in the Prospectus and agrees to be bound by them;
- represent, warrant and undertake that the allotment of or application for the Hong Kong Offer Shares to the underlying applicant or by underlying applicant or for whose benefit this application is made would not require the Company to comply with any requirements under any law or regulation (whether or not having the force of law) of any territory outside Hong Kong;
- agree that this application, any acceptance of it and the resulting contract, will be governed by and construed in accordance with the laws of Hong Kong; and
- agree that the Company, the Joint Global Coordinators, the Sole Sponsor, the Joint Bookrunners, the Joint Lead Managers, the Underwriters and their respective directors, advisors, agents and any other parties involved in the Global Offering are entitle to rely on any warranty, representation and declaration made by us or the underlying applicants.

我們確認已(i)遵照電子公開發售指引及透過銀行/股票經紀遞交白表eIPO申請的運作程序以及我們就香港公開發售提供白表eIPO服務的所有適用法例及規例(無論法定與否);及(ii)閱讀 程及本申請表格所載的條款和條件及申請程序,並同意受其約束。為代表與本申請有關的相關申請人作出申請,我們:

- 按招股章程及本申請表格所載條款及條件,並在遵守組織章程大綱及組織章程細則的情況下,申請認購以下數目的香港發售股份;
- 隨附申請認購香港發售股份所需的全數款項(包括1%經紀佣金、0.0027%證監會交易 徵費及0.005%聯交所交易費);
- 確認相關申請人已承諾及同意接納彼等根據本申請所申請認購的香港發售股份,或任何較少數目的香港發售股份;
- 承諾及確認相關申請人及相關申請人為其利益而提出申請的人士並無申請認購或已申請 認購或承購或表示有意認購或收取或獲配售或分配(包括有條件及/或暫定),亦將不會 申請認購或承購或表示有意認購國際發售的任何發售股份,亦無參與國際發售;
- 明白本公司與聯席全球協調人將依賴此等聲明及陳述,以決定是否就本申請配發任何香 港發售股份,及相關申請人如作出虛假聲明,可能會遭受檢控;
- 授權本公司將相關申請人的姓名/名稱列入本公司股東名冊內,作為配發予彼等的任何香港發售股份的持有人,而本公司及/或其代理(在符合本申請表格所載條款及條件的規限下)根據本申請表格及招股章程所載程序向相關申請人任何寄發股票及/或任何退款支票及/或電子退款指示(如適用)、除非相關申請人申請認贈1,000,000股或以上香港發售股份,並按本申請表格及招股章程所載程序親身領取任何股票;
- 要求把任何電子退款指示發送到相關申請人以單一銀行賬戶繳付申請股款的付款賬戶;
- 要求任何以多個銀行賬戶繳付申請股款的相關申請人的退款支票以相關申請人為抬頭 人,並根據本申請表格及招股章程所述程序將任何有關退款支票以普通郵遞方式寄發到 申請所列的地址,郵誤風險概由相關申請人自行承擔;
- 確認各相關申請人已細閱本申請表格及招股章程所載條款及條件以及申請程序,並同意

 學其約古:
- **聲明、保證及承諾**向相關申請人或由相關申請人或為其利益而提出本申請的人士配發或 由該等人士申請香港發售股份,不會引致本公司須遵從香港以外任何地區的法例或規例 的任何規定(不論是否具法律效力);
- 同意本申請、申請獲接納及因而產生的合約,均受香港法例管轄,並按其詮釋;及
- 同意本公司、聯席全球協調人、獨家保薦人、聯席賬簿管理人、聯席牽頭經辦人、包銷商、彼等各自的董事、顧問、代理及參與全球發售的任何其他人士有權依賴於吾等或相關申請人作出的任何保證、聲明或陳述。

Signature 簽名 Date 日期 Name of signatory 簽署人姓名/名稱 Capacity We, on behalf of Hong Kong Offer Shares on behalf of the underlying applicants whose details are contained in the underlying applicants, offer to purchase Total number of Hong Kong Offer Shares the read-only CD-ROM submitted with this Application Form. 代表相關申請人提出認購的香港發售股份(申請人的詳細資料載於連同本申請表格遞交的 我們(代表相關 申請人)提出認購 3 A total of Cheque(s) Cheque number(s) 支票編號 a total sum of 其總金額為 銀行名稱

港元

1	Please	use	вьоск	letters	請用正楷填寫

Name of White Form eIPO Service Provider 白表 eIPO 服務供應商名稱			
Chinese Name 中文名稱	White Form eIPO Service Provider ID 白表eIPO服務供應商編號		
Name of contact person 聯絡人姓名	Contact number 聯絡電話號碼	Fax number 傳真號碼	
Address 地址		se 此欄供經紀填寫 申請由以下經紀遞交	
	Broker No. 經紀號碼		
	Broker's Chop 經紀印章		